Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

Patel Viralkumar; Keating Michael J.; Wierda William G.; Gandhi Varsha

首页> 外文期刊>Leukemia and lymphoma >Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

【24h】

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

机译：TP-0903（一种AXL抑制剂）和B-PAC-1（一种促胰蛋白酶活性的化合物）与依鲁替尼的临床前组合在慢性淋巴细胞性白血病中的应用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia and lymphoma》 |2016年第6期|共4页
作者
Patel Viralkumar; Keating Michael J.; Wierda William G.; Gandhi Varsha;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 在乳腺癌中应用CRISPR/Cas9筛选发现一种动粒-微管依赖的Aurora-A抑制剂耐药机制 [J] . 陈艾琳, 林永辉, 王自峰, 癌症（英文版） . 2021,第008期
2. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia [J] . Patel Viralkumar, Keating Michael J., Wierda William G., Leukemia and lymphoma . 2016,第6期

机译：TP-0903（一种AXL抑制剂）和B-PAC-1（一种促胰蛋白酶活性的化合物）与依鲁替尼的临床前组合在慢性淋巴细胞性白血病中的应用
3. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors [J] . Sinha Sutapa, Boysen Justin, Nelson Michael, Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第9期

机译：靶向AXL抑制将慢性淋巴细胞白血病B细胞凋亡，并表现出与BTK抑制剂组合的协同/添加剂效应
4. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia [J] . Aw Andrew, Brown Jennifer R. Leukemia and lymphoma . 2017,第9a10期

机译：Bcl-2抑制剂和伊布勒替尼的潜在组合作为慢性淋巴细胞白血病的前线治疗
5. Proteomics-based target deconvolution of clinical multi-kinase inhibitors inducing apoptosis in primary chronic lymphocytic leukemia cells (CLL) [C] . Marcus Bantscheff, Ulrich Kruse, Christian P. Pallasch, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：基于蛋白质组学的临床多激酶抑制剂诱导肾凋亡凋亡的靶碎屑（CLL）
6. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
7. Preclinical combination of TP-0903 an AXL inhibitor and B-PAC-1 a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia [O] . Viralkumar Patel, Michael J. Keating, William G. Wierda, -1

机译：TP-0903（一种AXL抑制剂）和B-PAC-1（一种促胰蛋白酶活性的化合物）与依鲁替尼的临床前组合在慢性淋巴细胞性白血病中的应用
8. Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare [O] . Paul J. Hampel, Timothy G. Call, Wei Ding, 2019

机译：在伊布勒替尼治疗的慢性淋巴细胞白血病患者进展时添加威尼肽：联合疗法，以防止Ibrutinib Flare

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

著录项

相似文献

相关主题

期刊订阅